Dr. Derek DiRocco has served on Acrivon's Board since November 2021. He has been a partner at RA Capital Management since December 2020, having joined as a principal in December 2017, focusing on company formation and evidence-based healthcare and life-science investing. He currently serves on the boards of Mineralys Therapeutics, Evommune, Rivus Pharmaceuticals and Forward Therapeutics, with past directorships including iTeos Therapeutics, Connect Biopharma, Werewolf Therapeutics, 89bio, IDRx and CanBridge. Dr. DiRocco holds a B.A. in biology from the College of the Holy Cross and a Ph.D. in pharmacology from the University of Washington, and conducted post-doctoral research at Brigham and Women's Hospital / Harvard Medical School. He serves on Acrivon's Audit and Nominating & Corporate Governance Committees.